Oncoinvent Radspherin Phase 2 Milestone
Analysis based on 7 articles · First reported Jun 18, 2026 · Last updated Jun 18, 2026
The announcement of Oncoinvent reaching a significant recruitment milestone for Radspherin's Phase 2 trial is a positive signal for the company and the broader radiopharmaceutical market. It suggests progress in bringing a new treatment option to market for ovarian cancer, potentially increasing investor confidence in Oncoinvent and similar clinical-stage biotech firms.
Oncoinvent, a clinical-stage radiopharmaceutical company, announced that its Phase 2 trial for Radspherin, an alpha-emitting therapy for peritoneal metastases from ovarian cancer, has reached the 50% patient recruitment milestone. A total of 54 patients have been enrolled, representing half of the planned trial population. Recruitment has accelerated significantly in 2026, surpassing total enrollment for 2025. Ten hospitals across the United States, Spain, Norway, Belgium, the United Kingdom, and Italy are actively participating, with more sites opening. Øystein Soug, CEO of Oncoinvent, highlighted the strong commitment of investigators and the encouraging safety and preliminary efficacy signals from earlier studies.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard